Stock listing

Munich:3371 Corbus Pharmaceuticals Holdings, Inc. Aktie

German listing (Munich) of Corbus Pharmaceuticals Holdings, Inc. · home listing NASDAQ:CRBP

Follow Corbus Pharmaceuticals Holdings, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CRBP

$2.06 USD -0.38 (-15.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRBP

Past year -82.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.01 – $2.48 USDNov 20, 2026
Volume
1.38M sharesNov 20, 2026
Market cap
$42.45M USDAt the close on Nov 20, 2026 · price × 20.61M shares outstanding
52-week range
$2.01 – $12.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$6.72M USDMedian day 790,150 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Corbus Pharmaceuticals Holdings, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRBP · Home$2.06 USD-0.375 (-15.4%)1,380,532$2.43$2.48$2.01$2.435Close on Nov 20, 2026
LSE:0SZI$2.16 USD-0.36 (-14.3%)21,596$2.39$2.45$2.12$2.52Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRBP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.06-0.375-15.4%$2.43$2.48$2.011,380,532
$2.435-0.31-11.3%$2.72$2.88$2.415660,429
$2.745-0.265-8.8%$2.96$3.003$2.62635,314
$3.01-0.365-10.8%$3.29$3.34$2.953570,863
$3.375-0.015-0.4%$3.41$3.62$3.00953,696
$3.39-0.02-0.6%$3.38$3.53$3.27573,400
$3.41-0.59-14.7%$4.00$4.01$3.231,050,900
$4.00+0.07+1.8%$4.04$4.20$3.80670,800
$3.93+0.41+11.6%$3.39$3.98$3.21643,000
$3.52+0.45+14.7%$3.11$3.745$3.111,243,300
$3.07+0.21+7.3%$2.93$3.125$2.91685,200
$2.86-0.71-19.9%$3.57$3.57$2.811,356,300
$3.57-0.30-7.8%$3.97$4.099$3.572,012,100
$3.87-0.045-1.1%$3.92$4.11$3.734,367,600
$3.915-0.305-7.2%$4.21$4.23$3.895673,200
$4.220.000.0%$4.20$4.31$3.952,317,200
$4.22-0.03-0.7%$4.25$4.34$4.101,482,200
$4.25+0.10+2.4%$4.13$4.27$4.085750,800
$4.15+0.16+4.0%$3.99$4.205$3.97716,600
$3.99-0.06-1.5%$4.05$4.076$3.87847,300
$4.05-0.08-1.9%$4.08$4.08$3.93372,900
$4.13-0.155-3.6%$4.37$4.52$4.032983,800
$4.285-0.135-3.1%$4.45$4.565$4.28625,900
$4.42-0.04-0.9%$4.48$4.68$4.405477,600
$4.46-0.06-1.3%$4.54$4.67$4.38734,900
$4.52+0.19+4.4%$4.35$4.72$4.221,065,300
$4.33-0.08-1.8%$4.40$4.62$4.231,089,700
$4.41-0.37-7.7%$4.72$4.82$4.371,340,000
$4.78-0.49-9.3%$5.24$5.26$4.76648,300
$5.27-0.11-2.0%$5.35$5.403$5.111,010,700
$5.38+0.11+2.1%$5.25$5.61$5.171867,900
$5.27-0.22-4.0%$5.80$5.80$5.131,346,000
$5.49-0.29-5.0%$5.72$5.795$5.471,241,900
$5.78-0.07-1.2%$5.87$5.995$5.65707,400
$5.85-0.28-4.6%$6.17$6.17$5.83793,000
$6.13-0.21-3.3%$6.59$6.68$6.06834,800
$6.34-0.48-7.0%$6.80$6.82$6.25802,600
$6.82+0.19+2.9%$6.75$6.88$6.57507,000
$6.63-0.29-4.2%$6.93$7.05$6.59785,800
$6.92-0.22-3.1%$7.12$7.18$6.88932,000
$7.14-0.31-4.2%$7.50$7.59$6.97708,200
$7.45-0.29-3.7%$7.69$7.76$7.125757,800
$7.74-0.135-1.7%$7.83$7.98$7.66787,300
$7.875+0.225+2.9%$7.73$7.95$7.61452,800
$7.65+0.17+2.3%$7.51$7.79$7.42499,700
$7.48+0.22+3.0%$7.22$7.67$7.1541,155,000
$7.260.000.0%$7.26$7.38$7.03992,600
$7.26+0.34+4.9%$6.86$7.50$6.821,226,500
$6.92-1.16-14.4%$8.08$8.08$6.3253,749,600
$8.08-0.04-0.5%$7.93$8.70$7.668,396,500
$8.12-0.12-1.5%$8.38$8.495$7.952,347,300
$8.24-0.62-7.0%$8.75$8.79$8.21646,700
$8.86-1.735-16.4%$10.60$10.72$8.8451,003,800
$10.60-0.485-4.4%$11.07$11.07$10.31915,400
$11.08-0.38-3.3%$11.37$11.45$11.06222,500
$11.46-0.02-0.2%$11.52$11.60$11.22475,300
$11.48+0.20+1.8%$11.27$11.56$10.60664,400
$11.28+0.37+3.4%$10.81$11.37$10.58901,300
$10.910.000.0%$10.86$11.00$10.39473,600
$10.91-0.22-2.0%$11.13$11.29$10.75584,300
$11.13-0.17-1.5%$11.28$11.45$11.11325,900
$11.30-0.01-0.1%$11.36$11.55$10.96391,800
$11.31+0.62+5.8%$10.90$11.35$10.791,281,867
$10.69+0.31+3.0%$10.20$10.88$9.681,313,673
$10.38+0.54+5.5%$9.97$10.42$9.895604,000
$9.84-0.15-1.5%$10.00$10.05$9.73300,400

Splits

1 split · NASDAQ:CRBP · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
Munich:3371
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

All Corbus Pharmaceuticals Holdings, Inc. news

Corbus Pharmaceuticals Holdings, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 119 in all · newest Nov 16, 2026 · oldest 2019
Calls
3 calls with a replay · 3 with a transcript · latest Nov 10, 2020
Decks
46 decks · latest Nov 16, 2026

Where Corbus Pharmaceuticals Holdings, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRBP · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A3D54PLang & SchwarzGermanyEUR
gettex:3371gettexGermanyEUR
LS Exchange:A3D54PLS ExchangeGermanyEUR
BOATS:CRBPBOATSUnited StatesUSD
LSE:0SZILSEUnited KingdomUSD
Tradegate:3371TradegateGermanyEUR
Dusseldorf:3371DusseldorfGermanyEUR
Frankfurt:3371FrankfurtGermanyEUR
Hamburg:3371HamburgGermanyEUR
Munich:3371 · This pageMunichGermanyEUR
Stuttgart:3371StuttgartGermanyEUR

Valuation

Price/book 0.5× against a median of 4.2×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$68.98M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.85

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Arecor Therapeutics PLC · LSE:ARECUS$42.37MUS$38.32M48.8×17.1×n/a8.8×38.7%0.0×n/a
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.88MUS$32.02Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Prescient Therapeutics Limited · ASX:PTXUS$41.64MUS$35.80Mn/an/an/a4.4×n/a0.0×n/a
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Median of the othersUS$41.82MUS$25.90M48.8×18.6×4.2×−16.1%0.1×1.51

Forecasts

9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
33.22 USD · Analysts' mean
EPS, year to Dec 2026
-6.45 · 4 analysts
Revenue, year to Dec 2026
1.25M · 8 analysts

Team and board

Officers

OfficerRole
Yuval CohenChief Executive Officer and Director
Sean MoranChief Financial Officer
Ian HodgsonChief Operating Officer
G. Scott GoekenGeneral Counsel & Corporate Secretary
Christina BertschVP of Human Resources
Leonardo Viana NicacioChief Medical Officer
Nishant SaxenaChief Business Officer

Board

DirectorRole
Yuval CohenChief Executive Officer and Director

Events

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+11.7%
Q2 2026Aug 6, 2026 · Before open+1.8%
Q1 2026May 12, 2026 · Before open+3.5%
Q4 2025Mar 9, 2026+25.3%
Q3 2025Nov 12, 2025 · Before open+7.4%
Q2 2025Aug 5, 2025 · Before open−4.7%
Q1 2025May 6, 2025 · Before open−15.8%
Q4 2024Mar 10, 2025 · Before open0.0%
Q3 2024Nov 7, 2024 · Before open−2.1%
Q2 2024Aug 6, 2024 · Before open−3.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open+2.5%
Q4 2023Mar 12, 2024 · Before open+16.5%
Q3 2023Nov 7, 2023 · Before open−16.7%
Q2 2023Aug 8, 2023 · Before open−0.2%
Q1 2023May 9, 2023 · After close+5.0%
Q4 2022Mar 7, 2023 · Before open−6.7%
Q3 2022Nov 8, 2022 · After close−2.3%
Q2 2022Aug 9, 2022 · After close+0.0%
Q1 2022May 10, 2022 · Before open−2.7%
Q4 2021Mar 8, 2022 · Before open+7.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck55 slidesNov 16, 2026
Investor Presentation (October 2026)Investor deck62 slidesOct 15, 2026
Investor Presentation (September 2026)Investor deck58 slidesSep 14, 2026
Investor Presentation (May 2026)Investor deck58 slidesMay 26, 2026
Investor Presentation (March 2026)Investor deck63 slidesMar 9, 2026
Investor Presentation (February 2026)Investor deck61 slidesFeb 25, 2026
Investor Presentation (January 2026)Investor deck59 slidesJan 12, 2026
Investor Presentation (December 2025)Investor deck54 slidesDec 11, 2025
Investor Presentation (October 2025)Investor deck50 slidesOct 20, 2025
Investor Presentation (May 2025)Investor deck55 slidesMay 19, 2025
All 46 decks
DeckKindSlidesDate
Investor Presentation (February 2025)Investor deck54 slidesFeb 14, 2025
Investor Presentation (November 2024)Investor deck63 slidesNov 7, 2024
Investor Presentation (November 2024)Investor deck63 slidesNov 4, 2024
Investor Presentation (August 2024)Investor deck75 slidesAug 6, 2024
Investor Presentation (June 2024)Investor deck73 slidesJun 3, 2024
Investor Presentation (February 2024)Investor deck67 slidesFeb 5, 2024
Investor Presentation (January 2024)Investor deck66 slidesJan 26, 2024
Investor Presentation (November 2023)Investor deck58 slidesNov 14, 2023
Obesity Week 2023Conference15 slidesOct 16, 2023
Investor Presentation (August 2023)Investor deck46 slidesAug 3, 2023
Investor Presentation (March 2023)Investor deck42 slidesMar 7, 2023
Investor Presentation (February 2023)Investor deck40 slidesFeb 13, 2023
Investor Presentation (November 2022)Investor deck32 slidesNov 8, 2022
Investor Presentation (June 2022)Investor deck19 slidesJun 8, 2022
Investor Presentation (April 2022)Investor deck29 slidesApr 11, 2022
Investor Presentation (July 2021)Investor deck54 slidesJul 22, 2021
Investor Presentation (June 2021)Investor deck46 slidesJun 1, 2021
Conference Presentation (January 2021)Conference26 slidesJan 27, 2021
Technical Presentation (November 2020)Technical34 slidesNov 16, 2020
Technical Presentation (November 2020)Technical33 slidesNov 10, 2020
Investor Presentation (November 2019)Investor deck46 slidesNov 25, 2019
Investor Presentation (September 2018)Investor deck44 slidesSep 20, 2018
Investor Presentation (January 2018)Investor deck56 slidesJan 8, 2018
Investor Presentation (November 2017)Investor deck45 slidesNov 9, 2017
Investor Presentation (August 2017)Investor deck12 slidesAug 31, 2017
Investor Presentation (August 2017)Investor deck40 slidesAug 22, 2017
Investor Presentation (June 2017)Investor deck45 slidesJun 7, 2017
Investor Presentation (May 2017)Investor deck49 slidesMay 9, 2017
Technical Presentation (March 2017)Technical46 slidesMar 30, 2017
Technical Presentation (March 2017)Technical90 slidesMar 13, 2017
37th Annual Cowen Health Care Conference (March 2017)Conference43 slidesMar 8, 2017
Technical Presentation (November 2016)Technical33 slidesNov 14, 2016
Investor Presentation (June 2016)Investor deck37 slidesJun 16, 2016
Investor Presentation (January 2016)Investor deck33 slidesJan 11, 2016
Investor Presentation (February 2015)Investor deck27 slidesFeb 9, 2015
Investor Presentation (November 2014)Investor deck26 slidesNov 10, 2014

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$75M raised · Jefferies LLC +1
Dealers: Jefferies LLC (co-lead), Piper Sandler & Co. (co-lead)
Use of proceeds: Fund clinical development of its pipeline, working capital and general corporate purposes
Nov 12, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000881.7K3.94M36.1M4.82M2.44M1.91M
Cost of revenue233.0K600.0K31.2M1.49M1.64M98.3K89.6M48.6M26.0M15.4M
Gross profit-233.0K-600.0K-31.2M-1.49M-757.5K3.94M-53.5M-43.8M-23.6M-13.5M
Research and development70.1M32.2M31.2M16.1M36.4M98.3M89.6M48.6M26.0M15.4M
Selling, general and administrative15.2M16.5M13.9M18.7M20.4M28.5M23.6M13.0M8.96M6.46M
Operating income-85.3M-48.7M-45.1M-39.8M-56.0M-122.8M-77.1M-56.7M-32.6M-20.0M
Depreciation and amortization233.0K588.0K641.0K763.0K999.8K1.12M739.4K493.9K255.7K87.7K
EBITDA-85.1M-48.1M-44.4M-39.1M-55.0M-121.7M-76.4M-56.3M-32.3M-19.9M
Interest expense01.87M3.86M3.10M2.71M1.13M003.63K3.12K
Income before tax-78.5M-40.2M-44.6M-42.3M-45.6M-111.3M-71.5M-55.7M-32.4M-20.0M
Income tax0013.5M-87.8K35.0K-2.30M1.08M-396.9K13.6K
Net income-78.5M-40.2M-44.6M-42.3M-45.6M-111.3M-71.5M-55.7M-32.4M-20.0M
Earnings per share, basic-5.90-3.68-10.31-10.15-11.15-1.42-1.12-0.98-0.65-0.49
Earnings per share, diluted-5.90-3.68-10.31-10.15-11.15-1.42-1.12-0.98-0.65-0.49

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents28.5M17.2M13.7M17.0M25.0M85.4M31.7M41.7M62.5M15.0M
Short-term investments134.8M131.9M7.18M42.2M72.6M0159.0K150.0K
Receivables1.50M2.58M2.68M1.33M
Inventory350.0K-2.68M00
Current assets167.0M153.0M23.5M60.2M100.2M92.1M38.2M44.2M65.5M17.4M
Property, plant and equipment159.0K385.0K973.0K1.61M2.39M4.07M5.08M2.71M1.43M435.3K
Goodwill00
Total assets168.2M155.9M28.3M66.3M107.7M102.3M49.1M47.0M67.0M17.9M
Accounts payable2.21M4.79M3.18M2.17M1.78M7.38M11.1M6.35M3.13M3.42M
Current liabilities20.7M11.8M31.9M12.6M17.0M31.9M34.9M18.1M8.20M8.90M
Long-term debt016.0M15.6M18.0M05.00K
Total debt1.63M3.24M17.9M21.6M21.2M21.2M9.45M394.3K332.9K276.4K
Total liabilities20.7M13.5M35.2M33.3M38.6M57.0M43.0M19.5M9.19M8.97M
Shareholders' equity147.5M142.4M-6.91M33.0M69.1M45.3M6.16M27.5M57.8M8.92M
Shares outstanding17.6M12.2M4.42M4.17M4.17M98.9M64.7M57.2M55.6M44.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-64.5M-41.8M-36.1M-37.5M-48.2M-99.7M-45.7M-30.1M-27.8M-13.6M
Capital spending-7.00K00-13.4K-54.2K-484.5K-2.74M-2.30M-707.4K-353.0K
Free cash flow-64.5M-41.8M-36.1M-37.6M-48.2M-100.2M-48.5M-32.4M-28.5M-13.9M
Cash from investing-1.64M-121.3M35.6M30.1M-73.4M-484.5K-2.74M-2.30M-707.4K-353.0K
Cash from financing77.4M166.6M-2.82M-533.6K60.8M154.9M38.5M11.4M76.0M16.7M
Dividends paid00
Share buybacks142.2M40.7M12.1M78.9M16.7M
Change in cash11.3M3.47M-3.28M-8.00M-60.8M54.7M-10.00M-20.9M47.5M2.82M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 2, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
8-K · Current reportOct 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 30, 2026Big-stake noticeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
424B5 · ProspectusAug 7, 2026Offer documentSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
8-K · Current reportJul 6, 2026Material contractSEC
S-8 · Registration statement for employee plansJun 17, 2026Offer documentSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 29, 2026Offer documentSEC
8-K · Current reportMay 26, 2026Current reportSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 21, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
8-K · Current reportMay 14, 2026Management or board changeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
8-K · Current reportApr 16, 2026Management or board changeSEC
8-K · Current reportApr 14, 2026Current reportSEC
8-K · Current reportApr 7, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 2, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 2, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 2, 2026Meeting noticeSEC
424B3 · ProspectusMar 25, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 23, 2026Other filingsSEC
CORRESP · Letter to the SECMar 18, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 13, 2026Other filingsSEC
S-3 · Registration statementMar 11, 2026Offer documentSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
8-K · Current reportFeb 25, 2026Current reportSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 16, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 15, 2025Big-stake noticeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
8-K · Current reportDec 11, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 3, 2025Material contractSEC
424B5 · ProspectusNov 3, 2025Offer documentSEC
8-K · Current reportOct 30, 2025Current reportSEC
424B5 · ProspectusOct 30, 2025Offer documentSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
8-K · Current reportOct 20, 2025Current reportSEC
8-K · Current reportSep 16, 2025Current reportSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 1, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 1, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 1, 2025Meeting noticeSEC
8-K · Current reportMar 21, 2025Management or board changeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
8-K · Current reportMar 18, 2025Management or board changeSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
144 · Notice of proposed saleMar 6, 2025Other filingsSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
8-K · Current reportFeb 14, 2025Current reportSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportDec 3, 2024Current reportSEC
8-K · Current reportNov 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportNov 4, 2024Current reportSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
144 · Notice of proposed saleSep 4, 2024Other filingsSEC
8-K · Current reportSep 3, 2024Current reportSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
8-K · Current reportAug 20, 2024Management or board changeSEC
8-K · Current reportAug 6, 2024Current reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Current reportSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportJun 3, 2024Current reportSEC
S-8 · Registration statement for employee plansMay 31, 2024Offer documentSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 20, 2024Management or board changeSEC
8-K · Current reportMay 9, 2024Current reportSEC
144 · Notice of proposed saleMay 8, 2024Other filingsSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
DEFA14A · Additional proxy materialApr 10, 2024Meeting noticeSEC
8-K · Current reportApr 10, 2024Management or board changeSEC
ARS · Annual report to shareholdersApr 2, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 2, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 2, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 22, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMar 21, 2024Other filingsSEC
8-K · Current reportMar 20, 2024Current reportSEC
10-K/A · Annual report, amendedMar 20, 2024Annual reportSEC
424B3 · ProspectusMar 20, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedMar 18, 2024Big-stake noticeSEC
CORRESP · Letter to the SECMar 18, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 15, 2024Other filingsSEC
S-3 · Registration statementMar 13, 2024Offer documentSEC
10-K · Annual reportMar 12, 2024Annual reportSEC
8-K · Current reportMar 12, 2024ResultsSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipFeb 29, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 29, 2024Insider tradeSEC

This page holds 200 of 812 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Corbus Pharmaceuticals Holdings, Inc.’s releases · as of Nov 6, 2026

Common shares
20,606,760
Fully diluted
20,606,760

Fully diluted

LineSharesAs of
Common shares20,606,760Nov 6, 2026

Share count over time

CountShares
Nov 6, 202620,606,760
Sep 30, 202620,606,760

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Cormorant Asset Management, LP2.34M11.4%US$16MSep 30, 2026
Ra Capital Management, L.P.1.91M9.3%US$13.1MSep 30, 2026
BlackRock1.75M8.5%US$11.9MSep 30, 2026
Mpm Bioimpact LLC1.67M8.1%US$11.4MSep 30, 2026
Orbimed Advisors LLC1.67M8.1%US$11.4MSep 30, 2026
Vanguard995K4.8%US$6.79MSep 30, 2026
Jones Hill Capital LP886K4.3%US$6.05MSep 30, 2026
Sio Capital Management, LLC766K3.7%US$5.23MSep 30, 2026
Caption Management, LLC475K2.3%US$3.24MSep 30, 2026
Geode Capital451K2.2%US$3.07MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
AQR Capital Management LLC335K1.6%US$2.29MSep 30, 2026
Marshall Wace, LLP308K1.5%US$2.1MSep 30, 2026
Susquehanna300K1.5%US$2.04MSep 30, 2026
State Street262K1.3%US$1.78MSep 30, 2026
Dimensional210K1.0%US$1.43MSep 30, 2026
ADAR1 Capital Management, LLC195K0.95%US$1.33MSep 30, 2026
Exome Asset Management LLC191K0.93%US$1.3MSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.181K0.88%US$1.24MSep 30, 2026
Prosight Management, LP168K0.82%US$1.15MSep 30, 2026
UBS139K0.68%US$950KSep 30, 2026
Goldman Sachs128K0.62%US$873KSep 30, 2026
Northern Trust127K0.62%US$868KSep 30, 2026
Fidelity127K0.62%US$866KSep 30, 2026
Nuveen116K0.56%US$788KSep 30, 2026
Stonepine Capital Management, LLC95,0000.46%US$648KSep 30, 2026
Renaissance Technologies94,9000.46%US$647KSep 30, 2026
Morgan Stanley93,0850.45%US$635KSep 30, 2026
Point72 Asset Management, L.P.89,3120.43%US$609KSep 30, 2026
HSBC87,1730.42%US$592KSep 30, 2026
Advisory Services Network, LLC85,3510.41%US$582KSep 30, 2026
DAFNA Capital Management LLC83,2480.40%US$568KSep 30, 2026
Millennium81,2690.39%US$554KSep 30, 2026
XTX Topco Ltd79,9520.39%US$545KSep 30, 2026
BNP Paribas78,2740.38%US$534KSep 30, 2026
Doliver Advisors, LP75,9750.37%US$518KSep 30, 2026
Walleye Capital LLC75,7950.37%US$517KSep 30, 2026
Schwab64,8310.31%US$442KSep 30, 2026
Rangeley Capital, LLC61,4000.30%US$419KSep 30, 2026
Verdad Advisers, LP60,5660.29%US$413KSep 30, 2026
Simplex Trading, LLC47,8570.23%US$326KSep 30, 2026
BNY45,2820.22%US$309KSep 30, 2026
D. E. Shaw & Co., Inc.39,5020.19%US$269KSep 30, 2026
Driehaus Capital Management LLC38,9770.19%US$266KSep 30, 2026
Panagora Asset Management Inc35,5050.17%US$242KSep 30, 2026
LMR Partners LLP35,5000.17%US$242KSep 30, 2026
Barclays35,1440.17%US$240KSep 30, 2026
Cantor Fitzgerald, L. P.30,0000.15%US$205KSep 30, 2026
Velan Capital Investment Management LP30,0000.15%US$205KSep 30, 2026
Bank of America29,6410.14%US$202KSep 30, 2026
Sectoral Asset Management Inc28,0000.14%US$191KSep 30, 2026

This page holds 50 of 114 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund534K2.6%US$5MJun 30, 2026
iShares Russell 2000 ETF407K2.0%US$3.82MJun 30, 2026
Vanguard Extended Market Index Fund208K1.0%US$1.95MJun 30, 2026
Fidelity Small Cap Index Fund180K0.87%US$1.61MJul 31, 2026
iShares Russell 2000 Value ETF157K0.76%US$1.47MJun 30, 2026
Fidelity Extended Market Index Fund83,2880.40%US$659KMay 31, 2026
Dimensional U.S. Small Cap ETF58,3830.28%US$524KJul 31, 2026
iShares Micro-Cap ETF55,3520.27%US$519KJun 30, 2026
Schwab Small-Cap Index Fund39,7020.19%US$356KJul 31, 2026
U.S. Micro Cap Portfolio31,5460.15%US$283KJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Master Small Cap Index Series30,7720.15%US$289KJun 30, 2026
Fidelity Total Market Index Fund27,1930.13%US$215KMay 31, 2026
U.S. Small Cap Portfolio26,8110.13%US$240KJul 31, 2026
Fidelity Series Total Market Index Fund23,5760.11%US$186KMay 31, 2026
Fidelity Small Cap Value Index Fund23,0020.11%US$216KJun 30, 2026
Nuveen Small Cap Blend Index Fund22,3080.11%US$200KJul 31, 2026
Avantis U.S. Small Cap Equity ETF22,0530.11%US$174KMay 31, 2026
Schwab Total Stock Market Index Fund20,0000.10%US$179KJul 31, 2026
EQ/2000 Managed Volatility Portfolio17,7780.09%US$167KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund17,4900.08%US$164KJun 30, 2026
Fidelity Nasdaq Composite Index Fund12,7460.06%US$101KMay 31, 2026
LVIP State Street Small-Cap Index Fund12,7000.06%US$119KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund12,5720.06%US$118KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund11,4200.06%US$107KJun 30, 2026
U.S. Vector Equity Portfolio10,5120.05%US$94,293Jul 31, 2026
Small Cap Index Fund8,6180.04%US$80,837Jun 30, 2026
Fidelity ZERO Total Market Index Fund8,2080.04%US$73,626Jul 31, 2026
Global X Russell 2000 ETF7,8620.04%US$70,522Jul 31, 2026
VIP Disciplined Small Cap Portfolio7,7830.04%US$73,005Jun 30, 2026
Vanguard Balanced Index Fund7,6350.04%US$71,616Jun 30, 2026
Fidelity ZERO Extended Market Index Fund6,1120.03%US$54,825Jul 31, 2026
EQ/AB Small Cap Growth Portfolio4,8400.02%US$45,399Jun 30, 2026
EQ/Small Company Index Portfolio4,8400.02%US$45,399Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund4,7340.02%US$42,464Jul 31, 2026
Small-Cap Index Portfolio4,6680.02%US$43,786Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF4,2290.02%US$37,934Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio4,0000.02%US$37,520Jun 30, 2026
Small Cap Index Trust3,9640.02%US$37,182Jun 30, 2026
1290 VT Micro Cap Portfolio3,7440.02%US$35,119Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio3,6600.02%US$34,331Jun 30, 2026
NVIT Small Cap Index Fund3,6210.02%US$33,965Jun 30, 2026
JNL/DFA U.S. Small Cap Fund3,3050.02%US$31,001Jun 30, 2026
BlackRock Advantage SMID Cap V.I. Fund3,0630.01%US$28,731Jun 30, 2026
Fidelity Flex Small Cap Index Fund2,7610.01%US$24,766Jul 31, 2026
BlackRock Advantage Small Cap Growth Fund2,6850.01%US$25,185Jun 30, 2026
Dimensional US Core Equity Market ETF2,6800.01%US$24,040Jul 31, 2026
DWS Small Cap Index VIP2,5720.01%US$24,125Jun 30, 2026
1290 VT Small Cap Value Portfolio2,5650.01%US$24,060Jun 30, 2026
T. Rowe Price Small-Cap Index Fund2,5110.01%US$23,553Jun 30, 2026
U.S. Core Equity 1 Portfolio2,3740.01%US$21,295Jul 31, 2026

This page holds 50 of 81 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Cormorant Asset Management, LP
Other: Former 10% Owner
Sale425,000USD 4.10US$1.74MOct 29, 2026
Ben Yong
Director
Sale2,000USD 7.84US$15,680Sep 14, 2026
Saxena Nishant C
Officer: Chief Business Officer
Buy2,600USD 9.63US$25,038Aug 11, 2026
Moran Sean F.
Officer: Chief Financial Officer
Sale12,000USD 10.08US$121KAug 7, 2026
Cohen Yuval
Director, Officer: Chief Executive Officer
Sale17,000USD 10.08US$171KAug 7, 2026
Altmeyer Anne
Director
Sale2,412USD 7.91US$19,079Jun 10, 2026
Jenkins John Kenneth
Director
Sale4,800USD 7.91US$37,968Jun 10, 2026
Kung Winston
Director
Sale2,026USD 7.91US$16,026Jun 10, 2026
Saxena Nishant C
Officer: Chief Business Officer
Buy9,000USD 7.58US$68,220Jun 3, 2026
Saxena Nishant C
Officer: Chief Business Officer
Buy4,500USD 7.33US$32,985Jun 2, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.9.90%1.91MSep 23, 2026Schedule 13G
Mpm Bioimpact LLC8.60%1.67MSep 30, 2026Schedule 13G
Cormorant Asset Management, LP7.76%1.5MOct 31, 2026Schedule 13G
BlackRock, Inc.5.90%1.09MJun 30, 2026Schedule 13G
Orbimed Advisors LLC5.90%718KDec 31, 2024Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
George Golumbeski
Other companies: Acumen Pharmaceuticals, Inc. (Chairman of its Board of Directors · Since at least Nov 6, 2025); Mural Oncology plc (Director · Since at least Jul 30, 2024); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Sage Therapeutics Inc (Director · Since at least Jan 22, 2019); Enanta Pharmaceuticals, Inc. (Director · Feb 7, 2014 – Feb 26, 2020 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past)
Director · Jul 6, 2020 – Jul 6, 2020 · Past
Rachelle Jacques
Other companies: uniQure N.V. (Director · Since at least Oct 21, 2021); Akari Therapeutics PLC (Chief Executive Officer, Director · Jan 1, 2024 – Apr 26, 2024 · Past); Viela Bio Inc (Director · Mar 15, 2021 – Mar 15, 2021 · Past)
Director · Since at least Jun 17, 2021
Winston Kung
Other companies: ArriVent BioPharma, Inc. (Chief Financial Officer · Since at least Jan 25, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past)
Director · Since at least Aug 16, 2024
Avery W Catlin
Other companies: Provention Bio Inc (Director · Sep 5, 2018 – Apr 27, 2023 · Past); Celldex Therapeutics, Inc. (Sr. VP & CFO · Jan 6, 2006 – Sep 2, 2016 · Past)
Director · Nov 24, 2014 – May 30, 2024 · Past
Brent Pfeiffenberger
Other companies: Century Therapeutics, Inc. (President and CEO, Director · Since at least Dec 4, 2023); Butterfly Network, Inc. (President and CEO, Director · Mar 7, 2024 – Mar 7, 2024 · Past)
Director · Since at least May 13, 2026
David P. Hochman
Other companies: Orchestra BioMed Holdings, Inc. (See Remarks, Director · Since at least Jan 26, 2023); Motus GI Holdings, Inc. (Director · Feb 13, 2018 – Feb 13, 2019 · Past)
Director · Nov 10, 2017 – May 20, 2020 · Past
Renu Gupta
Other companies: Insmed Incorporated (Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past); Agenus Inc. (Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past)
Director · Nov 24, 2014 – May 25, 2017 · Past
Sean Moran
Other companies: InVivo Therapeutics Holdings Corp (Acting Chief Financial Officer · Aug 22, 2013 – Sep 3, 2013 · Past); Imunon, Inc. (Chief Financial Officer · Dec 2, 2008 – Mar 17, 2009 · Past)
Chief Financial Officer · Since at least Nov 24, 2014
Dominic Smethurst
Other companies: Bicycle Therapeutics PLC (Chief Medical Officer · Aug 10, 2020 – Jan 3, 2023 · Past)
Chief Medical Officer · Since at least Feb 27, 2024
John Kenneth Jenkins
Other companies: Provention Bio Inc (Director · Aug 10, 2020 – Apr 27, 2023 · Past)
Director · Since at least Jun 5, 2018
All 26 people
PersonSeat
Leonardo Viana Nicacio
Other companies: Protara Therapeutics, Inc. (Chief Medical Officer · Since at least Apr 15, 2025)
Chief Medical Officer · Since Jul 6, 2026
Paris Panayiotopoulos
Other companies: The Medicines Company (Director · May 30, 2019 – Jan 6, 2020 · Past)
Director · May 22, 2019 – May 22, 2019 · Past
Peter Salzmann
Other companies: Immunovant, Inc. (Chief Executive Officer, Director · Dec 18, 2019 – Apr 16, 2025 · Past)
Director · Mar 6, 2020 – May 30, 2024 · Past
Yong Ben
Other companies: BridgeBio Oncology Therapeutics, Inc. (Chief Medical and Development Officer · Since at least Aug 11, 2025)
Director · Since at least Mar 6, 2023
Alan F HolmerDirector · Since at least May 18, 2022
Anne AltmeyerDirector · Since at least Sep 26, 2022
Barbara WhiteChief Medical Officer · Nov 24, 2014 – Feb 2, 2021 · Past
Christina BertschVP of Human Resources · Since at least Nov 5, 2026
Craig Stuart MillianChief Operating Officer · Feb 2, 2021 – Feb 13, 2023 · Past
G. Scott GoekenGeneral Counsel & Corporate Secretary · Since at least Nov 5, 2026
Ian HodgsonChief Operating Officer · Since at least Mar 13, 2025
Mark TepperPresident and CSO · Nov 24, 2014 – Jan 18, 2019 · Past
Nishant SaxenaChief Business Officer · Since at least May 21, 2026
Rachael Louise BrakeChief Scientific Officer · Dec 6, 2021 – Feb 13, 2023 · Past
Robert Paul DiscordiaChief Operating Officer · Aug 6, 2019 – Mar 17, 2020 · Past
Yuval CohenChief Executive Officer and Director · Since at least Nov 10, 2017

Open People

Log in to ask 6ix AI your own questions about Corbus Pharmaceuticals Holdings, Inc.